## **Respiratory Syncytial Virus (RSV)**

## **Overview**

RSV is a common respiratory virus that usually causes mild, cold-like symptoms.<sup>1</sup> Most people infected recover in a week or two, but RSV can be serious, especially for infants and older adults. RSV is responsible for 2.1 million outpatient visits, over 200,000 hospitalizations, and up to 13,000 deaths each year.<sup>2</sup> RSV is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the U.S. Almost all children will have had an RSV infection by the age of 2 years.<sup>3</sup> It is also a significant cause of respiratory illness in older adults.<sup>1</sup> Prior to 2020, RSV followed predictable seasonal patterns in the U.S. A typical RSV season ran between October and May, with the most cases in early February. However, because of restrictions on activity and behavior changes due to the COVID-19 pandemic, RSV has not been spreading in its usual pattern since 2020. We don't know when, or if, the predictable seasonal spreading of RSV will return.<sup>2</sup>

**CLOROXPRO** 

About the Pathogen & Infection Control Measures						
Infectious Agent (Pathogen) <sup>4.5</sup>	Agent Type: Virus Taxonomy: Family: Pneumoviridae Genus: Orthopneumovirus	<ul> <li>Species: Human orthopneumovirus</li> <li>Subtypes: A and B</li> <li>Synonym(s): RSV, Human respiratory syncytial virus (hRSV), Pneumovirus</li> <li>Characteristics: Enveloped virus</li> </ul>				
<ul> <li>Infectious Characteristics Definitions:</li> <li>Incubation period—the time from exposure to infection with symptoms.</li> <li>Period of communicability—time when a pathogen can be transmitted from one person to another.</li> </ul>	Risk factors for severe infection: <sup>6</sup>	<ul> <li>Age: Infants and children younger than two years old and older adults, especially 65 years and older</li> <li>Pre-existing conditions: Weakened immune system, neuromuscular disorders, chronic heart disease, or lung disease</li> </ul>				
	Incubation period: <sup>3</sup>	4–6 days				
	Period of communicability:6	<ul> <li>3–8 days after symptom onset</li> <li>Up to 4 weeks in infants and those who are immunocompromised</li> </ul>				
	Signs & symptoms: <sup>3</sup>	<ul> <li>Symptoms appear in stages:</li> <li>Runny nose, decreased appetite, coughing, sneezing, fever, wheezing</li> <li>In very young infants: irritability, decreased activity, and breathing difficulties</li> </ul>				
	Duration of illness: <sup>3</sup>	Most RSV infections resolve on their own within a week or two				
	Severity of illness: <sup>3</sup>	Severity ranges from mild to more severe infections such as bronchiolitis and pneumonia				
<b>Mode(s) of Transmission</b> <sup>5</sup> How the Infection Spreads	Contact: Direct from person-person when an infected person coughs or sneezes and indirect from contaminated					
Survival on Surfaces <sup>7</sup>	7–8 hours					
Immunization/Prophylaxis/ Treatment	An RSV vaccine has been approved by the FDA for individuals 60 years of age and older and pregnant women to protect newborns. <sup>8</sup> An RSV vaccine for the general public, including infants and children, is not available at this time. There is a monoclonal antibody treatment administered monthly during the RSV season to high-risk infants. <sup>9</sup>					
Infection Control Measures	<ul> <li>General Measures For All Spaces</li> <li>commercial buildings, K–12 schools, healthcare):<sup>6</sup></li> <li>Practice respiratory hygiene and cough etiquette (e.g., covering coughs and sneezes).</li> <li>Perform frequent hand hygiene.</li> <li>Stay home when ill.</li> <li>Encourage those who are sick to stay home and limit contact with others.</li> <li>Develop non-punitive sick leave policies</li> </ul>		<ul> <li>Healthcare-Specific Measures:<sup>10</sup></li> <li>Isolation Precautions: Contact + Standard Precautions for the duration of illness. Extend duration of contact precautions for immunocompromised patients due to prolonged shedding</li> <li>PPE: Gown and gloves. Mask according to Standard Precautions to prevent respiratory droplets from coming into contact with mucous membranes</li> <li>Linen: Per routine</li> <li>Waste management: per routine</li> </ul>			
Cleaning & Disinfection <sup>11</sup>	Standard cleaning & disinfection p ed with the virus. Use EPA-registe		reased frequency of high-touch surfaces that may be contaminat- h an RSV claim.			

## **Clorox Product Recommendations**

The following CloroxPro cleaner-disinfectants can be used to effectively manage RSV on environmental surfaces and equipment.

Products for use against Respiratory Syncytial Virus (RSV)					EPA Reg. No.	RSV contact time
Clorox Clorox Ec	oClean Disinfecting Clea	ner and Ref				
tem No. 60213	32 fl. oz. Spray	9/case				
tem No. 60094		4/case			67619-45	30 seconds
		-1 6036				
CloroxPro EcoCle	an Disinfecting Cleaner Wi	pes				
tem No. 60605	75 ct. Canister	6/case			67619-48	5 minutes
					07019-40	Sminules
CloroxPro Cloro	x Germicidal Bleach					
tem No. 30966	121 fl. oz. Bottle	3/case				
				CT100	67619-32	5 minutes
				En al anti-		
CloroxPro Clean	-Up Disinfectant Cleaner	with Bleach	1	52		
tem No. 35417	32 fl. oz. Spray	9/case			67610 17	20
tem No. 35420	128 fl. oz. Refill	4/case			67619-17	30 seconds
tem No. 15949	x Disinfecting Wipes 75 ct. Canister	6/case	- resh Scent			
tem No. 15949 tem No. 15948	75 ct. Canister 75 ct. Canister		-resh Scent _emon Scent		67610 01	15 occurrents
					67619-31	15 seconds
tem No. 31547	700 ct. Bucket		Fresh Scent			
tem No. 31428	700 ct. Bucket Refill	2/case F	Fresh Scent			
	x Disinfecting Spray					
tem No. 38504	19 fl. oz. Aerosol Spray	12/case		2020	67619-21	30 seconds
Clorox Healthca	re Bleach Germicidal Wip	es				
tem No. 30577	6" x 5" 150 ct. Canister	6/case				
tem No. 35309	6.75" x 9" 70 ct. Canister	6/case				
tem No. 32621	6.75" x 9" 100 ct. Softpack	9/case		TAXING CAF	67619-12	1 minute
tem No. 31424	12" x 12" 50 ct. Carton	6/case				
tem No. 30358	12" x 12" 110 ct. Bucket	2/case		With Address of the A		
tem No. 30359	12" x 12" 110 ct. Bucket Refill	2/case				
	re VersaSure Cleaner Dis		ipes			
tem No. 31757	6.75" x 8" 85 ct. Canister	6/case				
tem No. 31758	6" x 5" 150 ct. Canister	6/case		MARTINE TRANSPORT	56392-7	30 seconds
tem No. 31759	12" x 12" 110 ct. Bucket	2/case		Contraction of States and States		
tem No. 31761	12" x 12" 110 ct. Bucket Refill			Management Management		
Clorox Healthcar tem No. 30828	e Hydrogen Peroxide Clear 32 fl. oz. Spray	ner Disinfect 9/case	tant Cleaner			
tem No. 30829	128 fl. oz. Refill	4/case			67619-24	30 seconds
	re Hydrogen Peroxide Clea		ctant Wipes			
tem No. 30824	6.75" x 9" 95 ct. Canister	6/case				
tem No. 30825	6.75" x 5.75" 155 ct. Canister				67619-25	30 seconds
tem No. 30826	12" x 11" 185 ct. Bucket	2/case		Constant Barrier Barrier Barrier Barrier Barrier		
tem No. 30827	12" x 11" 185 ct. Bucket Refill					
	re Fuzion Cleaner Disinfe			The		
tem No. 31478	32 fl. oz. Spray	9/case			67619-30	1 minute
Jorox Healthcare	Spore <sup>10</sup> Defense Cleaner Dis	sinfectant				
Clorox Healthcare tem No. 32122	128 fl. oz. for Sprayer Devices					
					67619-40	1 minute

sment/respiratory-syncytial-virus.html

## References:

- 1. CDC. Respiratory Syncytial Virus Infection (RSV). [Internet]. [cited 2023 May 24]. Available from https://www.cdc.gov/rsv/index.html.
- 2. CDC. Surveillance of RSV. [Internet]. [cited 2024 Sept 3]. Available from https://www.cdc.gov/rsv/php/surveillance/index.html
- 3. CDC. Symptoms of RSV [Internet]. [cited 2024 Sept 3]. Available from https://www.cdc.gov/rsv/symptoms/index.html
- 4. WHO. Respiratory syncytial virus (RSV) disease [Internet]. [cited 2024 Sept 3]. Available from: https://www.who.int/teams/health-product-policy-and-standards/ standards-and-specifications/norms-and-standards/vaccine-standardization/respiratory-syncytial-virus-disease
- 5. Government of Canada. Pathogen Safety Data Sheets: Infectious Substances Respiratory syncytial virus [Internet]. [cited 2023 Jun 1]. Available from: https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/respiratory-syncytial-vi
- 6.CDC. How RSV Spreads [Internet]. [cited 2024 Sept 3]. Available from: https://www.cdc.gov/rsv/causes/
- 7. Wißmann, J. E., Kirchhoff, L., Brüggemann, Y., et al. (2021). Persistence of pathogens on inanimate surfaces: A narrative review. Microorganisms, 9(2), 343. 8. CDC. RSV Vaccines [Internet]. [cited 2024 Sept 3]. Available from https://www.cdc.gov/rsv/vaccines
- 9. SYNAGIS (palivizumab) for prevention of Severe RSV Disease [Internet]. [cited 2023 Jun 1]. Available from: https://www.synagis.com/what-is-synagis.html 10. CDC. Isolation Precautions Guideline [Internet]. [cited 2024 Sept 3]. Available from https://www.cdc.gov/infection-control/hcp/isolation-precautions/index.html



For product resources and implementation tools, contact your Clorox sales representative, call 800-492-9729 or visit www.CloroxPro.com

© 2024 Clorox Professional Products Company, 1221 Broadway, Oakland, CA 94612